SGN-CD48A is a novel humanized anti-cd48 antibody-drug conjugate being tested for the treatment of multiple myeloma.

SparkCures ID 303
Developed By Seattle Genetics
Generic Name SGN-CD48A
Treatment Classifications
Treatment Targets

Clinical Trials


There are no resources, links or videos to display for this treatment.

SparkCures Verified

SparkCures is working closely with Seattle Genetics to provide the most up-to-date information on this treatment. Use the button above to add this treatment to your list of favorites.

Learn more about how we work with industry partners